[HTML][HTML] mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy

T Tian, X Li, J Zhang - International journal of molecular sciences, 2019 - mdpi.com
The mammalian or mechanistic target of rapamycin (mTOR) pathway plays a crucial role in
regulation of cell survival, metabolism, growth and protein synthesis in response to upstream …

[HTML][HTML] Emerging roles for mammalian target of rapamycin (mTOR) complexes in bladder cancer progression and therapy

J Huan, P Grivas, J Birch, DE Hansel - Cancers, 2022 - mdpi.com
Simple Summary The mammalian target of rapamycin (mTOR) pathway promotes cell
growth and metabolism in response to growth factors, nutrients, and cellular energy status …

Luteolin suppresses bladder cancer growth via regulation of mechanistic target of rapamycin pathway

K Iida, T Naiki, A Naiki‐Ito, S Suzuki, H Kato… - Cancer …, 2020 - Wiley Online Library
Luteolin is a natural flavonoid with strong anti–oxidative properties that is reported to have
an anti–cancer effect in several malignancies other than bladder cancer. In this study, we …

BBN as an urothelial carcinogen

C Vasconcelos-Nóbrega, A Colaço, C Lopes… - In Vivo, 2012 - iv.iiarjournals.org
Experimental urinary bladder tumours have been proposed as a useful model for the study
of urinary bladder carcinogenesis, as well as for evaluating new therapeutic strategies …

[HTML][HTML] Abnormal protein glycosylation and activated PI3K/Akt/mTOR pathway: role in bladder cancer prognosis and targeted therapeutics

C Costa, S Pereira, L Lima, A Peixoto, E Fernandes… - PLoS …, 2015 - journals.plos.org
Muscle invasive bladder cancer (MIBC, stage≥ T2) is generally associated with poor
prognosis, constituting the second most common cause of death among genitourinary …

Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma

H Zaryouh, I De Pauw, H Baysal… - Medicinal research …, 2022 - Wiley Online Library
Resistance to therapies targeting the epidermal growth factor receptor (EGFR), such as
cetuximab, remains a major roadblock in the search for effective therapeutic strategies in …

mTOR inhibitors in urinary bladder cancer

R Pinto-Leite, R Arantes-Rodrigues, N Sousa… - Tumor Biology, 2016 - Springer
Despite the great scientific advances that have been made in cancer treatment, there is still
much to do, particularly with regard to urinary bladder cancer. Some of the drugs used in …

In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer

R Arantes-Rodrigues, A Colaco, R Pinto-Leite… - Anticancer …, 2013 - ar.iiarjournals.org
Several drugs have shown in vitro and in vivo pharmacological activity against urinary
bladder cancer. This review aims at compiling the different drugs evaluated in in vitro and in …

Mitochondrial and liver oxidative stress alterations induced by N‐butyl‐N‐(4‐hydroxybutyl)nitrosamine: relevance for hepatotoxicity

MM Oliveira, JC Teixeira… - Journal of Applied …, 2013 - Wiley Online Library
The most significant toxicological effect of nitrosamines like N‐butyl‐N‐(4‐hydroxybutyl)
nitrosamine (BBN) is their carcinogenic activity, which may result from exposure to a single …

In vivo and in vitro effects of RAD001 on bladder cancer

C Vasconcelos-Nóbrega, R Pinto-Leite… - … Oncology: Seminars and …, 2013 - Elsevier
Objective To evaluate the influence of Everolimus (RAD001) on chemically induced
urothelial lesions in mice and its influence on in vitro human bladder cancer cell lines …